Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013/05/22 by Stuart A. Scott, S A Scott, K Sangkuhl +15 · 973 citations
Chemistry · Medicine · #Adverse effect #Antiplatelet Therapy and Cardiovascular Diseases #Aspirin #Biology #CYP2C19 #Clopidogrel #Conventional PCI #Cytochrome P450 #Diabetes Treatment and Management #Gene #Genetics #Genotype #Guideline #Internal medicine #Medicine #Myocardial infarction #P2Y12 #Pathology #Percutaneous coronary intervention #Pharmacogenetics #Pharmacology #Platelet #Platelet aggregation inhibitor #Prodrug #Synthesis of β-Lactam Compounds
paper · pdf · doi:10.1038/clpt.2013.105
published in Clinical Pharmacology & Therapeutics 94(3), 317-323 (Wiley)
openalex publication_date 2013/05/22 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/02
Abstract
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for CYP2C19 genotype-directed antiplatelet therapy, refined recommendations for specific CYP2C19 alleles, and additional evidence from an expanded literature review (updates at http://www.pharmgkb.org).
Citations
Cited by
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
- Prioritizing Genomic Applications for Action by Level of Evidence: A Horizon-Scanning Method
- Health Data Cooperatives – Citizen Empowerment
- Pharmacogenomic considerations in opioid analgesia
- Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis
- Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. [europepmc]
- CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? [europepmc]
- Clinical pharmacogenetics implementation: approaches, successes, and challenges. [europepmc]
- PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. [europepmc]
- Emerging roles for pharmacists in clinical implementation of pharmacogenomics. [europepmc]
- Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. [europepmc]
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. [europepmc]
- Integrating pharmacogenomics into electronic health records with clinical decision support. [europepmc]
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. [europepmc]
- Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. [europepmc]
- Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. [europepmc]
- Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. [europepmc]
- Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. [europepmc]
- Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. [europepmc]
- Personalized Medicine and the Power of Electronic Health Records. [europepmc]
- Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. [europepmc]
- Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. [europepmc]
- The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. [europepmc]
- Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. [europepmc]
- The ChinaMAP analytics of deep whole genome sequences in 10,588 individuals. [europepmc]
- PharmVar GeneFocus: CYP2C19. [europepmc]
- Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. [europepmc]
- Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y 12 Inhibitor Therapy: A Meta-Analysis. [europepmc]
- Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. [europepmc]
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. [europepmc]
Related